Zydus receives Final approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP

Zydus receives final approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP Ahmedabad, 23 May, 2019 Zydus Cadila has received the final approval from the USFDA to market Esomeprazole Magnesium Delayed-Release Capsules USP (US RLD – NEXIUM), 25 mg and 40 mg. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad. Esomeprazole belongs to the group of medicines termed as proton pump inhibitors. Esomeprazole reduces the amount of acid secreted by the stomach. It is used to treat the symptoms of gastroesophageal reflux disease, to reduce the risk of stomach ulcers in some people taking pain medicines, to treat patients with stomach infection (Helicobacter pylori) along with certain antibiotics and long- term treatment of conditions where stomach makes too much acid. The group now has 266 approvals and has so far filed over 350 ANDAs since the commencement of the filing process in FY 2003-04. About Zydus Cadila Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 23,000 people worldwide and is dedicated to creating healthier communities globall y. Zydus aspires to be a research-based pharmaceutical company by 2020. ***

The release as fetched from its publisher. zyduslife.com ↗